Novo Nordisk to present new cardiometabolic and renal data, including with semaglutide, at Kidney Week 2024, ObesityWeek®, The Liver Meeting®, and AHA Scientific Sessions 2024
-- Data unveils new insights into treatment for type 2 diabetes, obesity,
cardiovascular, kidney and liver diseases
-- Cardiometabolic diseases, including cardiovascular disease, obesity,
type 2 diabetes, and MASH, are increasing in prevalence in the U.S. and
are associated with high disease burden and increased medical costs(1-4
)
-- Multiple presentations planned at Kidney Week 2024, ObesityWeek(®), The
Liver Meeting(®), and American Heart Association (AHA) Scientific
Sessions 2024
PLAINSBORO, N.J., Oct. 23, 2024 /PRNewswire/ -- Novo Nordisk today announced that new clinical trial data spanning the company's research and industry-leading cardiometabolic portfolio, will be presented across four medical congresses, building on the company's focus on driving change to defeat serious chronic disease and improve patient care.
These upcoming presentations will add to the data about semaglutide's effects on cardiometabolic conditions and build on previously presented findings.
"Cardiometabolic diseases represent some of the most significant health challenges facing the world today. Our cardiometabolic research is deepening our understanding of the interconnected nature of chronic conditions such as diabetes, obesity, cardiovascular, kidney, and liver diseases," said Michelle Skinner, PharmD, Vice President, Medical Affairs at Novo Nordisk. "Through research, we aim to further explore treatment options for those most affected, aligning with our commitment to advance scientific frontiers in chronic disease management."
A significant number of Americans are affected by cardiometabolic diseases, which have been on the rise during the last several decades.(1) T2D and cardiovascular disease (CVD) are highly prevalent,(5,6 )and CVD is the leading cause of death in the U.S.(7) Having either obesity or CKD increases the risk of developing interconnected cardiometabolic disease.(8-10) The obesity epidemic also is contributing to the increasing global prevalence of MASH (metabolic dysfunction-associated steatohepatitis), a serious chronic condition caused by the buildup of extra fat in the liver and characterized by liver inflammation and injury, with or without fibrosis.(11-14) The totality of Novo Nordisk data to be presented at these upcoming congresses will further highlight Novo Nordisk's commitment to researching serious, chronic diseases.
"Patients with cardiometabolic disease face a host of comorbid conditions. Improving care for them by helping reduce their risk of developing serious, potentially life-threatening complications is at the core of Novo Nordisk's research and development program, and this will be reflected in our upcoming data presentations," said Michelle Skinner. "We are excited to share our growing body of data investigating semaglutide and its potential to provide broader benefits to patients living with these common and intractable diseases."
Select Novo Nordisk abstracts to be presented, these data for semaglutide are investigational:
American Society of Nephrology, Kidney Week 2024, October 23 to 27 [San Diego]
Abstract Title Abstract presentation
details
Chronic Kidney Disease
Impact of Semaglutide on Infections and COVID-19: Data from the Late Breaking Oral
Presentation
FLOW Trial
October 25
4:50 PM PT
Effect of Semaglutide on Mortality Outcomes in the FLOW Trial Late Breaking Oral
Presentation
October 25
5:00 PM PT
Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of Late Breaking Oral
Presentation
CKD Severity in the FLOW Trial
October 26
11:15 AM PT
ObesityWeek(®) 2024, November 3 to 6 [San Antonio]
Abstract Title Abstract presentation
details
Obesity
Effects of Semaglutide 2.4 mg on Healthcare Costs in Patients With
Poster?086
November 3
Obesity and ASCVD (SHINE?ASCVD)
7:30 - 8:30 PM CT
Semaglutide Effect on Knee Osteoarthritis Pain and Walking Distance
Poster?095
November 3
by Age, Sex and Weight Loss
7:30 - 8:30 PM CT
A Real?World Analysis of Clinical Outcomes in Patients Using
Poster?106
November 3
Semaglutide 2.4 mg for 12 Months
7:30 - 8:30 PM CT
Semaglutide Reduces Hospital Admissions in Patients with Obesity or Oral Presentation
November 3
Overweight and Established CVD
2:30 - 2:45 PM CT
The SELECT CVOT: Old Lessons and New Learnings Oral Presentation
November 4
10:00 - 11:30 AM CT
Real?World Life Expectancy and Cardiovascular Event?Free Life?Year
Poster? 423
November 4
Gains With Semaglutide in the UK
2:30 - 3:30 PM CT
The American Association for the Study of Liver Diseases (The Liver Meeting(®)) 2024, November 15 to 19 [San Diego]
Abstract Title Abstract presentation
details
Obesity
Semaglutide improves liver enzymes and fatty liver index in patients
To be announced
with obesity and cardiovascular disease - results from the SELECT
trial
Non-Product
Exploring Predictors of Rapid Progression to Major Adverse Liver
To be announced
Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease
Understanding Metabolic Dysfunction-Associated Steatohepatitis:
To be announced
Differences in Clinical and Demographic Characteristics Across Racial
and Ethnic Groups
American Heart Association Scientific Sessions 2024, November 16 to 19 [Chicago]
Abstract Title Abstract presentation details
Obesity
Semaglutide and cardiovascular outcomes by blood pressure in the Moderated Digital Poster-
MDP747
November 17
SELECT trial
3:55 - 4:00 PM CT
Semaglutide Improves Cardiovascular Outcomes in Patients with a Oral Presentation- 4171808
November 18
History of Coronary Artery Bypass Surgery and Overweight or
1:30 - 1:41 PM CT
Obesity: The SELECT Trial
Type 2 Diabetes
Persistence to once weekly GLP-1 RAs is associated with lower risk of Moderated Digital Poster-
MDP1020
November 17
MI, stroke, and 2-point MACE among patients with T2D and ASCVD in
9:50 - 9:55 AM CT
the real world
Chronic Kidney Disease
Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Oral Presentation- 4171199
November 18
Cardiovascular Status or Risk in the FLOW trial
2:04 - 2:16 PM CT
Non-Product
Estimating obesity-attributable cardiovascular disease burden in the
Poster- Sa3003
November 16
United States: a Bayesian network analysis
10:30 - 11:30 AM CT
Prevalence and Clinical Characteristics of US Patients with Systemic
Poster- Mo1004
November 18
Inflammation and Atherosclerotic Cardiovascular Disease with or
10:30 - 11:30 AM CT
Without Chronic Kidney Disease
About Cardiometabolic Diseases
Cardiometabolic diseases encompass some of the most significant health challenges facing the world today. These common conditions, which often overlap and can coexist in the same patient, include CVD and metabolic diseases, such as T2D, obesity, and MASH.(15,16)
A significant proportion of the cardiovascular risk associated with these diseases is attributable to shared metabolic risk factors.(16) CVD accounts for around 70% of deaths in people living with obesity and is the leading cause of death in people with T2D, CKD and MASH.(9,16, 17,18)
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With its U.S. headquarters in New Jersey and commercial, production, and research facilities in seven states plus Washington DC, Novo Nordisk employs approximately 8,000 people throughout the country. For more information, visit novonordisk-us.com, Facebook, Instagram, X, LinkedIn, and YouTube.
_______________
References
1. Reiter-Brennan C, Dzaye O, Davis D, et al. Comprehensive care models for
cardiometabolic disease. Curr Cardiol Rep. 2021;23(3):22. Published 2021
Feb 24. doi:10.1007/s11886-021-01450-1.
2. Jardim TV, Mozaffarian D, Abrahams-Gessel S, et al. Cardiometabolic
disease costs associated with suboptimal diet in the United States: A
cost analysis based on a microsimulation model. PLoS Med.
2019;16(12):e1002981. Published 2019 Dec 17.
doi:10.1371/journal.pmed.1002981.
3. MedlinePlus: Non-alcoholic fatty liver disease. Available at:
https://medlineplus.gov/genetics/condition/non-alcoholic-fatty-liver-dise
ase/. Last Accessed October 2024.
4. American Liver Foundation. NASH definition & prevalence. Last updated
July 2, 2021. Last accessed: October 2024. Available at:
https://liverfoundation.org/for-patients/about-the-liver/diseases-of-the-
liver/nonalcoholic-steatohepatitis-information-center/nash-definition-pre
valence/.
5. Centers for Disease Control and Prevention. Type 2 Diabetes. Last
accessed September 2024. Available at:
https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html.
6. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular
Diseases and Risk Factors, 1990-2019. J Am Coll Cardiol.
2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010.
7. Centers for Disease Control and Prevention. Leading Causes of Death. Last
accessed: September 2024. Available at:
https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.
8. Valenzuela PL, Carrera-Bastos P, Castillo-García A, et al. Obesity and
the risk of cardiometabolic diseases. Nat Rev Cardiol.
2023;20(7):475-494. doi:10.1038/s41569-023-00847-5.
9. Jankowski J, Floege J, Fliser D, Böhm M, Marx N: Cardiovascular disease
in chronic kidney disease: pathophysiological insights and therapeutic
options. Circulation. 2021, 143:1157-72.
10.1161/CIRCULATIONAHA.120.050686.
10. Sanyal AJ, Husain M, Diab C, et al. Cardiovascular disease in patients
with metabolic dysfunction-associated steatohepatitis compared with
metabolic dysfunction-associated steatotic liver disease and other liver
diseases: A systematic review. Am Heart J Plus. 2024;41:100386.
Published 2024 Mar 24. doi:10.1016/j.ahjo.2024.100386.
11. Global Liver Institute. The language of NASH. Accessed August 29, 2023.
https://globalliver.org/wp-content/uploads/2022/06/GLI_TheLanguageofNASH
_270820.pdf.
12. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management
of nonalcoholic fatty liver disease: practice guidance from the American
Association for the Study of Liver Diseases. Hepatology.
2018;67(1):328-357.
13. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the
epidemic of nonalcoholic fatty liver disease demonstrates an exponential
increase in burden of disease. Hepatology. 2018;67(1):123-133.
14. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global
epidemiology of nonalcoholic fatty liver disease-Meta-analytic
assessment of prevalence, incidence, and outcomes. Hepatology.
2016;64(1):73-84.
15. Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of
the evidence. Cardiovasc Diabetol. 2023 Jul 31;22(1):195. doi:
10.1186/s12933-023-01937-x. PMID: 37525273; PMCID: PMC10391899.
16. Shroff H, VanWagner LB. Cardiovascular Disease in Nonalcoholic
Steatohepatitis: Screening and Management. Curr Hepatol Rep.
2020;19(3):315-326. doi:10.1007/s11901-020-00530-0.
17. Khafagy R, Dash S. Obesity and Cardiovascular Disease: The Emerging Role
of Inflammation. Front Cardiovasc Med. 2021;8:768119. Published 2021 Oct
25. doi:10.3389/fcvm.2021.768119.
18. Ma, CX., Ma, XN., Guan, CH. et al. Cardiovascular disease in type 2
diabetes mellitus: progress toward personalized management. Cardiovasc
Diabetol 21, 74 (2022). https://doi.org/10.1186/s12933-022-01516-6.
© 2024 Novo Nordisk All rights reserved. US24OB00483 October 2024
View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisk-to-present-new-cardiometabolic-and-renal-data-including-with-semaglutide-at-kidney-week-2024-obesityweek-the-liver-meeting-and-aha-scientific-sessions-2024-302284923.html
SOURCE Novo Nordisk Inc.
